Lectin‐complement pathway molecules are decreased in patients with cirrhosis and constitute the risk of bacterial infections

Lectin pathway molecules of the complement system are synthesized by hepatocytes and have pivotal role in innate host defence against infectious organisms. Ficolins (FCNs) act as soluble pattern recognition molecules, while mannan‐binding lectin serine proteases(MASPs) do as effector molecules in elimination of pathogens. We aimed to study the significance of low level of these molecules in the development of cirrhosis‐associated bacterial infections, which has not been elucidated so far.

[1]  P. Manoria,et al.  Immune Dysfunction in Cirrhosis , 2017, Journal of clinical and translational hepatology.

[2]  M. Papp,et al.  Macrophage activation marker, soluble CD163, is an independent predictor of short‐term mortality in patients with cirrhosis and bacterial infection , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[3]  A. Boldt,et al.  MBL-associated serine proteases (MASPs) and infectious diseases , 2015, Molecular Immunology.

[4]  William M. Lee,et al.  Circulating mannan‐binding lectin, M‐, L‐, H‐ficolin and collectin‐liver‐1 levels in patients with acute liver failure , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[5]  T. Kuijpers,et al.  Restoration of MBL-deficiency: redefining the safety, efficacy and viability of MBL-substitution therapy. , 2014, Molecular immunology.

[6]  D. Roelen,et al.  Genetic variation in TNFA predicts protection from severe bacterial infections in patients with end-stage liver disease awaiting liver transplantation. , 2014, Journal of hepatology.

[7]  M. Papp,et al.  Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[8]  M. Seidel,et al.  Mannan-binding lectin deficiency - Good news, bad news, doesn't matter? , 2012, Clinical immunology.

[9]  J. Chalmers,et al.  Human L-Ficolin (Ficolin-2) and Its Clinical Significance , 2012, Journal of biomedicine & biotechnology.

[10]  P. Kremsner,et al.  Ficolin-2 Levels and FCN2 Haplotypes Influence Hepatitis B Infection Outcome in Vietnamese Patients , 2011, PloS one.

[11]  F. Lammert,et al.  Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. , 2011, Journal of hepatology.

[12]  S. Thiel,et al.  Serum concentrations of lectin‐pathway components in healthy neonates, children and adults: mannan‐binding lectin (MBL), M‐, L‐, and H‐ficolin, and MBL‐associated serine protease‐2 (MASP‐2) , 2011, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[13]  G. Veres,et al.  Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis. , 2011, Human immunology.

[14]  A. Burroughs,et al.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. , 2010, Gastroenterology.

[15]  M. Papp,et al.  Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis. , 2010, Journal of hepatology.

[16]  S. Møller.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. , 2010, Journal of hepatology.

[17]  M. Poca,et al.  Toll‐like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients , 2010, Alimentary pharmacology & therapeutics.

[18]  F. Lammert,et al.  Nucleotide‐binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis , 2010, Hepatology.

[19]  V. Stadlbauer,et al.  Störungen des angeborenen Immunsystems bei akuten und chronischen Lebererkrankungen , 2009, Wiener klinische Wochenschrift.

[20]  J. Cowland,et al.  The Genetics of Ficolins , 2009, Journal of Innate Immunity.

[21]  Q. Hu,et al.  Specifically Binding of L-ficolin to N-glycans of HCV Envelope Glycoproteins E1 and E2 Leads to Complement Activation , 2009, Cellular and Molecular Immunology.

[22]  M. Petzl-Erler,et al.  Circulating levels of mannan‐binding lectin (MBL) and MBL‐associated serine protease 2 in endemic pemphigus foliaceus , 2008, Clinical and experimental dermatology.

[23]  P. Tandon,et al.  Bacterial infections, sepsis, and multiorgan failure in cirrhosis. , 2008, Seminars in liver disease.

[24]  S. Thiel.  Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. , 2007, Molecular immunology.

[25]  W. Ip,et al.  Mannose‐binding lectin in chronic hepatitis B virus infection , 2005, Hepatology.

[26]  A. Burroughs,et al.  Infection, coagulation, and variceal bleeding in cirrhosis , 2005, Gut.

[27]  M. Navasa,et al.  Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis , 2002, Hepatology.

[28]  A. Pauwels,et al.  Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients. , 1999, Journal of hepatology.

[29]  T. Poynard,et al.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.

[30]  T. Fujita,et al.  New insights into the role of ficolins in the lectin pathway of innate immunity. , 2015, International review of cell and molecular biology.

[31]  R. Pike,et al.  Mannose-binding lectin serine proteases and associated proteins of the lectin pathway of complement: two genes, five proteins and many functions? , 2012, Biochimica et biophysica acta.

[32]  E. Bhaskar,et al.  Prevalence and risk factors for bacterial skin infection and mortality in cirrhosis. , 2011, Annals of hepatology.

[33]  G. D’Amico,et al.  Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.

[34]  E. Strauss,et al.  A prospective study of bacterial infections in patients with cirrhosis. , 1993, Journal of hepatology.